MAIN ARTICLE
The Wegovy pill becomes a recovery engine
Novo reported third-quarter sales of 79.195 billion kroner, beating the 73.22 billion expected by analysts. Adjusted operating profit reached 31.72 billion kroner, up 27% at constant exchange rates and ahead of the 28.39 billion consensus estimate. These numbers suggest that demand for GLP-1 medicines remains substantial even as the company works to repair the growth trajectory that once made it Europe’s most valuable listed business.
The strongest contributor was oral Wegovy, launched in the United States in January. The pill generated nearly 5.4 billion kroner in the quarter, with American sales accounting for most of the total. An oral treatment may appeal to patients who prefer not to inject medication, giving physicians and individuals another option in the management of obesity. Strong initial sales, however, do not guarantee that demand will maintain the same pace indefinitely.
Novo estimates that its pill accounts for roughly 80% of new-to-brand prescriptions in the US oral obesity market, based on its defined channels and methodology. That is a commercial market-share measure, not a measure of medical efficacy or successful treatment outcomes. Decisions about medicine, dosage and suitability must still rest on clinical evidence, professional advice and a patient’s circumstances.

















